Efficacy and safety of fingolimod in stroke: A systemic review and meta-analysis

Table 4 Changes of T-lymphocytes with cluster of differentiation 8 expression/infarction or hematoma volume/modified Barthel index scores in the fingolimod and control groups

Ref.	Size of fingolimod group	Fingolimod group	Size of control group	Control group
CD8+ T cell count (mean ± SD, × 106/mL)1
Fu et al[15]	11	-0.16 ± 0.04	11	0.08 ± 0.08
Tian et al[18]	23	-0.09 ± 0.02	23	-0.02 ± 0.02
Lesion Volume (mean ± SD, mL)2
Fu et al[15]	11	9.91 ± 79.62	11	25.45 ± 75.45
Fu et al[16]	11	-1.97 ± 6.25	12	-1.35 ± 1.77
mBI score (mean ± SD)3
Fu et al[15]	11	72.7 ± 7.5	11	45.3 ± 10.9
Fu et al[16]	11	75.2 ± 4.7	12	65.4 ± 4.8

¹The outcome equaled CD8⁺ T cell count at 1 d after taking fingolimod orally minus CD8⁺ T cell count at baseline.

²Lesion volume consisted of infarct volume of AIS and hematoma volume of ICH. The outcome is lesion volume at 7 d after taking fingolimod orally minus lesion volume at baseline.

³The outcome is mBI score at 90 days after fingolimod taken orally minus mBI score at baseline.

CD8⁺ T cell: T-lymphocytes with cluster of differentiation 8 expression. Lesion volume: Infarction or hematoma volume; mBI score: Modified Barthel index score.